top of page
Open Book

Published Works

  • Lisak R, Truong D, Carroll W, Bhidayasiri R. International Neurology. Blackwell International. London 2009

  • Truong D, Dressler D, Hallett M. Manual of Botulinum Toxin Therapy. Cambridge University Presss. UK, 2009. (Bestseller)

  • Truong D, Le H, Nguyen H. Textbook of Clinical Neurology. Publisher: Yhoc, Vietnam. 928 pages, 2004.

  • Truong D, Pathak M, Frei K. Living well with Dystonia. Demos Publishing. In press.

  • Recent advances in Myoclonus and Paroxysmal Disorder. Stanley Fahn, Steven Frucht, Mark Hallett, Daniel Truong. Adv Neurol. 2002;89.

  • Pathak M, Frei K, Truong D. Handbook of spasmodic torticollis. Demos Publishing, 2003.

  • Truong D, Carroll W, Lisak R, Prabhakar S. Manual of International Neurology Diagnostics and Therapeutics”. Springer Verlag. In Preparation.


  • Fernandez H, Pappert E, Comella C, Evidente V, Truong, D., Verma A, Jankovic J. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naive Subjects with Cervical Dystonia." Tremor Other Hyperkinet Mov (N Y) 3, 2013

  • Tai, K. K. and Truong D. Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. PLoS One 8(4): e60309, 2013.

  • Truong D, S Gollomp, J Jankovic, P LeWitt, M Marx, A Hanschmann, H Fernandez. Sustained efficacy and safety of repeated incobotulinumtoxina (Xeomin®) injections in blepharospasm. J Neural Transm 120(9): 1345-1353, 2013.

  • Xiao J, Zhao Y, Truong D, Ledoux M. Role of Galpha(olf) in familial and sporadic adult-onset primary dystonia. Human Molecular Genetics. 22 (12): 2510-9, 2013.

  • Hauser R A, Truong D, Hubble J, Coleman C, Beffy J, Chang S, Picaut P. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm 120(2): 299-307, 2013.

  • Bhidayasiri R, Kaewwilai L, Wannachai N, Brenden N, Truong D, Devahastin R. Prevalence and diagnostic challenge of dystonia in Thailand: A service-based study in a tertiary university referral centre. Parkinsonism Relat Disord 17 S1: 15-19, 2011.

  • Comella C, Jankovic J, Truong D, Hanschmann A, Grafe S, the U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 308: 103-09, 2011

  • Tai KK, Truong D. (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells. Neurosci Lett. 2010 Oct 4;482(3):183-7.

  • Tai KK, Truong D. Memantine exacerbates myoclonic jerks in a rat model of posthypoxic myoclonus. Brain Research 1343:194–8, 2010.

  • Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timebaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in Cervical Dystonia. Parkinsonism and Related Disorders. 16: 316-23, 2010.

  • Tai KK, Pham L, Truong D. Idebenone Induces Apoptotic Cell Death in the Human Dopaminergic Neuroblastoma SHSY-5Y cells. Journal of Park Related Disorders. Submitted.

  • Jianfeng Xiao, Zhao Y, Bastian R, Perlmutter J, Racette B, Samer D. Tabbal, Karimi M, Paniello R, Wszolek Z, Uitti R, Van Gerpen J, Simon D, Tarsy D, Hedera P, Truong D, Frei K, Sat Dev Batish, Blitzer A, Pfeiffer R, Gong S, and Mark S LeDoux. Novel THAP1 Sequence Variants in Primary Dystonia. Neurology 74:229-38, 2010.

  • Jianfeng Xiao, Zhao Y, Bastian R, Perlmutter J, Racette B, Tabbal S, Karimi M, Paniello R, Wszolek Z, Uitti R, Van Gerpen J, Simon D, Tarsy D, Hedera P, Truong D, Frei K, Blitzer B, Pfeiffer R, Rudzińska M, Le C, Akano E, LeDoux M. The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia. Movement Disorders. In Press.

  • Tai K, Pham L, Truong D. Intracisternal Administration of Glibenclamide or 5-Hydroxydecanoate Does Not Reverse the Neuroprotective Effect of Ketogenic Diet Against Ischemic Brain Injury-Induced Neurodegeneration. Brain Injury. Brain Inj 13-14: 1081-8 2009.

  • Xiao J, Bastian R, Perlmutter J, Racette B, Tabbal S, Karimi M, Paniello R, Blitzer A, Batish S, Wszolek Z, Uitti R, Hedera P, Simon D, Tarsy D, Truong D, Frei K, Pfeiffer R, Gong S, Zhao Y, LeDoux M. High-throughput mutational analysis of TOR1A in primary dystonia. BMC Medical Genetics 2009, 10:24.

  • Truong D, Comella C, Fernandez H, Ondo W. Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: a randomized, placebo controlled, Phase II trial. Parkinsonism Relat Disord. 14(5):407-14, 2008.

  • Tai KK, Nguyen N, Pham L, Truong D. A Ketogenic Diet Prevents Cardiac Arrest-Induced Cerebral Ischemic Neurodegeneration. J Neural Transm. Jul;115(7):1011-7, 2008.

  • Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators (Participating Investigator). Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 71:481-5, 2008.

  • Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC; NET-D Investigators. Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 31(4):189-96, 2008.

  • Das CP, Prabhakar S and Truong D. Clinical profile of various sub-types of writer’s cramp. Journal of Parkinsonism and Related Disorders 13: 421–424, 2007.

  • Tai K and Truong D. NMDA receptor-mediated excitotoxicity contributes to the cerebral hypoxic injury of a rat model of posthypoxic myoclonus. Brain Research 1133: 209-15, 2007.

  • R. Pahwa, M. A. Stacy, S. A. Factor, K. E. Lyons, F. Stocchi, B. P. Hersh, L. W. Elmer, D. D. Truong, N. L. Earl. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology, 68: 1108 – 1115, 2007.

  • Tai KK and Truong D. Brivaracetam is Superior to Levetiracetam in a Rat Model of Post-Hypoxic Myoclonus. Journal Neural Transm 114:1547-1551, 2007.

  • Tai KK, Truong D. Ketogenic Diet Prevents Seizures and Reduces Myoclonic Jerks in Rats with Cardiac Arrest Induced Cerebral Hypoxia. Neuroscience Letters. 2007;425:34-38.

  • Pham P., Frei K.P., Woo W. and Truong D. Molecular defects of the dystonia-causing torsinA mutation. NeuroReport 17:1725-1728, 2006.

  • Truong D., Drake D. Duane, Joseph Jankovic, Carlos Singer et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders. 20; 783-91, 2005

  • Tai K. and Truong D. Post-hypoxic myoclonus induces Fos expression in the reticular thalamic nucleus and neurons in the brainstem. Brain Research, 1059; 122 – 128, 2005.

  • Frei K, Pathak M, Jenkins S, Truong.D. The natural history of posttraumatic cervical dystonia. Movement Disorders, 19:1492 – 1498, 2004.

  • Olanow CW, Kieburtz K, Stern M, Watts R, Langston MW, ….Truong D et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurology 61(10), 1563-1568, Oct 2004

  • Hauser R, Hubble J, Truong D. and the Istradefylline Study Group. Randomized Trial of the Adenosine A2a Receptor Antagonist Istradefylline in Advanced Parkinson’s Disease. Neurology 61:297-303,2003.

  • Tai K. and Truong D. Activation of ATP sensitive potassium channels confers protection against Rotenone-induced cell death: therapeutic implication for Parkinson’s disease. J Neurosci Res 2002 Aug 15;69(4):559-66. 

  • O'Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O'Neil T, Factor S, Seeberger L. Cervical dystonia severity scale reliability study. Mov Disord 2001 Nov;16(6):1086-1090

  • Frucht SJ, Fahn S, Greene PE, O'Brien C, Gelb M, Truong D, Welsh J, Factor S, Ford B. The natural history of embouchure dystonia. Mov Disord 2001 Sep;16(5):899-906

  • G. Kanthasamy, B. Q. Nguyen and Truong D. Animal Model of Posthypoxic Myoclonus: II. Neurochemical, Pathological and Pharmacological Characterization. Mov Disord. 2000;15 Suppl 1:31-8.

  • D. D. Truong, A. Kanthasamy, B. Nguyen, R. Matsumoto, P. Schwartz, Animal Models of Posthypoxic Myoclonus: I. Development and Validation. Mov Disord. 2000;15 Suppl 1:26-30.

  • Bang Q. Nguyen, A. G. Kanthasamy and D. Truong. Animal Models of Myoclonus: An Overview. Mov Disord. 2000;15 Suppl 1:22-25.

  • Matsumoto RR, Truong D, Nguyen KD, Dang AT, Hoang TT, Vo PQ, Sandroni P. Involvement of GABA(A) receptors in myoclonus.. Mov Disord. 2000;15 Suppl 1:47-52.

  • Kanthasamy AG, Tith T, Nguyen B, Tran A and Truong D. (1999), Antimyoclonic and neuroprotective effects of lamotrigine in an animal model of cardiac arrest. Restor Neurol Neurosci 1999;15(1):45-56.

  • Kanthasamy A, Yun JR, Nguyen B and Truong D. Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. J Pharmacol Exp Ther. 288(3):1340-8, 1999.

  • Truong D., Cullis P, O'Brien CF, Koller M, Villegas TF, Garces A, Wallace JD. Botbtm (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A resistant cervical dystonia patients. Movement Disorders: 12, 772-75, 1997.

  • Shannon KM, Bennett JP, Friedman JH and the Pramipexole Study Group. Efficacy of Pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 49(3):724-8, 1997.

  • Kanthasamy A, Kanthasamy A, Matsumoto R, Vu T and Truong D. Neuroprotective effects of strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in experimental model of Parkinson’s disease. Brain Research, 759; 1-8, 1997.

  • Jaw, S.P., Nguyen B, Vuong QTV, Trinh TA, Nguyen M and Truong D. Effects of GABA uptake inhibitors on posthypoxic myoclonus in rats. Brain Res Bul. 39, 189-92, 1996.

  • Matsumoto RR; Bowen WD; Walker JM; Patrick SL; Zambon AC; Vo VN; Truong D; De Costa BR; Rice KC. Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites. European Journal of Pharmacology, 301(1-3):31-40, 1996.

  • J.T. Cheng, Liu AW, Wasmuth J, Liu BP and Truong D. Anticipation in adult onset dystonia. Neurology 47(1):215-9, 1996.

  • Jaw SP, Su DD, Matsumoto RR, Truong D. Alterations of brain levels of phosphoinositidase-C-linked G11a/qa proteins in post-cardiac-arrest rats. Stroke 26, 1067-71, 1995.

  • Matsumoto RR, Aziz N and Truong D. Indol level in animal model of post-hypoxic myoclonus. Pharmacology, Bioch and Behavior, 50, 533-538, 1995.

  • Truong D.D., Sandroni P, Van Den Noort S, Matsumoto RR. Diphenhydramine is effective in the treatment of idiopathic dystonia. Archives of Neurology, 1995 Apr, 52(4):405-7.

  • Matsumoto RR, Nguyen DC and Truong D. Strychnine insensitive glycine site antagonists attenuate a cardiac arrest induced movement disorders. Eur J Pharmacol 275:117-123, 1995. 

  • Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong D and de Costa BR. Characterization of two novel sigma ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol. 280, 301-310, 1995.

  • Jaw SP, T. Dang and Truong D. Chronic treatments with 5-HT1A agonists attenuate posthypoxic myoclonus in rats. Pharmacol. Biochem. Behav. 52, 577-580, 1995.

  • Jaw SP, Su DD, Vuong QVT and Truong D. Regulation of tyrosine protein kinase receptor Trk-B and motor function in rats following cardiac arrest. Pharmacol. Biochem. Behav. 52, 443-446, 1995.

  • Matsumoto RR, Hussong MJ and Truong D. Effects of selective 5-HT ligands on post-hypoxic audiogenic myoclonus. Movement Disorders 10, 615-21, 1995.

  • Jaw SP, Su DD and Truong D. Astrocyte-derived growth factor (S100B) and motor function on rats following cardiac arrest. Pharmacol. Biochem. Behav. 52, 667-670, 1995.

  • van’t Groenewout JL, Stone MR, Vo VN, Truong D, Matsumoto RR. Evidence for the Involvement of histamine in the antidystonic effects of diphenhydramine. Exp. Neurol. 134, 253-260, 1995.

  • Kanthasamy A, Matsumoto RR, Gunasekar PG, and Truong D. Excitoprotective effect of felbamate in cultured cortical neurons. Brain Research. 705, 97-104, 1995.

  • Jaw, S.P., Su DD and Truong D. Expression of Bcl-2 and Bax in the frontal/parietal cortex of the rat following cardiac arrest. Brain Res Bul. 38(6) 577-580, 1995.

  • Kanthasamy A, Vu TQ, Yun RJ and Truong D. Antimyoclonic effects of gabapentin in animal model of myoclonus. Eur J Pharmacology. 546: 741-745, 1995.

  • Truong D, Matsumoto R, Schwartz PH, Hussong MJ, Wasterlain CG. Novel rat cardiac arrest model of posthypoxic myoclonus. Mov Disorders 9, 201-206, 1994.

  • Jaw SP, Hussong MJ, Matsumoto RR, Truong D. Involvement of 5-HT2 receptors in the post-hypoxic stimulus-sensitive myoclonus in rats. Pharmacology, Bioch and Behavior 49, 129-31, 1994.

  • Jamrozik Z, De Yebenes JG, Truong D, Cadet J. Intrastriatal infusion of amiloride increases rotations in 6-OHDA lesioned rats and “down-regulates” D2 receptors in the striatum and 5-HT2A receptors in the cortex. Pol J of Pharmacology 46, 417-22, 1994.

  • Kartsounis LD, Truong D, Morgan-Hughes JA, Harding AE: The Neuropsychological Features of Mitochondrial Myopathies and Encephalomyopathies. Archives of Neurology 49(2):158-160, 1992

  • Truong D, Rontal M, Rolnick M, Aronson AE, Mistura K: Double blind controlled study of botulinum toxin in adductor spasmodic dysphonia. The Laryngoscope Journal 101(6):630-634, 1991.

  • Truong D, Dubinski R, Hermanowicz N, Olson W, Silverman B, Koller W: Posttraumatic torticollis. Archives of Neurology 48: 221-23, 1991.

  • Rontal M, Rontal E, Rolnick M; Merson R, Silverman B, Truong D: A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: A preliminary report. The Laryngoscope Journal 101(8):911-914, 1991.

  • Fazzini E, Dwork AJ, Blum C, Burke R, Cote L, Goodman RR, Jacobs TP, Naini AB, Pezzoli G, Pullman, Solomon RA, Truong D, Weber CJ, Fahn S: Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism: One-year follow-up. Archives of Neurology 48(8): 813-820, 1991.

  • Sczesni, Becker H, Schroder J, Bittkau S, von Baumgarten F, Truong D, Przuntek H: Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases. Language: German. Wiener Klinische Wochenschrift 103(1):21-6, 1991.

  • Hermanowicz N, Truong D: Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 101:1216-1218. November 1991.

  • Truong D, Harding A, Morgan-Hughes JA, Marsden CD: Movement disorders in mitochondrial myopathies: A study of nine cases with two autopsy studies. Movement Disorders 5(2):109-117, 1990.

  • Truong D, Galloway M, Pezzoli G, Jamrozik A, Fahn S: Milacemide increased 5-hydroxytryptamine and dopamine levels in rat brain - Possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus. Pharmacology Biochemistry & Behavior 32:993-1001, 1989.

  • Truong D, Diamond B, Pezzoli G, Mena M, Fahn S: Monomine oxidase inhibitory properties of milacemide in rats. Life Science 44:1059- 66, 1989.

  • Truong D, Yebenes JG, Pezolli G, Jackson LV, Fahn S: Glycine involvement in DDT induced myoclonus. Movement Disorders 3(3):77-87, 1988.

  • Truong D, Fahn S: Therapeutic trial with glycine in myoclonus. Movement Disorders 3(3):222-232, 1988.

  • Truong D, Bressman S, Shale H, Fahn S: Clonazepam, haloperidol and clonidine in tic disorders. Southern Medical Journal 81:(9)1103-05, 1988.

  • Pezzoli AG, Fahn S, Truong D, et al: Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats. Brain Research 459:398-403, 1988. 

  • Cordova MA, Truong D, Blackburn JG: Preliminary neurologic and neurophysiologic findings in ectodermal dysplasias. Birth Defects 24(2):65-71, 1988.

  • Truong D, Sczesnii B, Fahn S, Gross J. et al: Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases. Language:German. Nervenarzt 59(2):103-09, 1988

  • Truong D, Dressler K, Hallett M. Foreword Clinical use of botulinum toxin. European Journal of Neurology 2006, 13 (Suppl. 1): 1

  • Truong D. Parkinson’s Disease Revisited. Journal of the Neurological Sciences 266: 196, 2008.

  • Truong D. Botulinum toxin Revisited. Journal of Neural Transmission. 115, 557, 2008

Invited Review Articles:
  • Truong D: Botulinum toxin therapy. Western Journal of Medicine 155(1):69-70, July 1991. 

  • Hermanowicz N and Truong D: Development of Botulinum toxin therapy. Western Journal of Medicine 163 (5): 472-73, 1995. 

  • Kanthasamy A, Matsumoto R and Truong D. Animal model of myoclonus. Special issue of Clinical Neuroscience 3(4):236-45, 1995-96.

  • Bhidayasiri R, Truong D. Peripheral dystonia. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at Accessed December 15, 2004.

  • Bhidayasiri, R. and Truong D. Expanding use of botulinum toxin. J Neurol Sci 235(1-2): 1-9, 2005.

  • Truong D., Bhidayasiri R. Botulinum toxin in laryngeal dystonia. Eur J Neurlogy. 13 (Suppl. 1): 36–41, 2006.

  • Bhidayasiri R., Cardoso F, Truong D. Botulinum toxin in blepharospasm and oromandibular dystonia. Eur J Neurology. 13 (Suppl. 1): 21-29, 2006

  • Frei K, Truong D, Dressler D. Botulinum Toxin Therapy of Hemifacial Spasm: Comparing Different Therapeutic Preparations. Eur J Neurology. 13 (Suppl. 1): 30-35, 2006.

  • Tai K.K., Bhidayasiri R., Truong D. Myoclonus: From Animal Model to Human. Journal of Parkinsonism and Related Disorders. 13: 377-381, 2007. 

  • Truong D. and Josh W. Botulinum toxin: Clinical application. Journal of Parkinsonism and Related Disorders.12 (6), 331-355, 2006. 

  • Watts CR, Truong D, Nye C. Evidence for the Effectiveness of Botulinum Toxin for Spasmodic Dysphonia from High-Quality Research Designs. Journal of Neural Transmission 115(4):625-30, 2008.

  • Truong D, Bhidayasiri R. Evidence for the Effectiveness of Botulinum Toxin in Sialorrhea. Journal of Neural Transmission 115(4):631-635, 2008.

  • Truong D, Bhidayasiri R, Wolters E. Management of nonmotor symptoms in advanced Parkinson’s disease. J Neurol Scien. 266: 216-228, 2008.

  • Bhidayasiri R , Truong D. Motor complications in Parkinson’s disease: clinical manifestations and management. J Neurol Scien. 266: 204-215, 2008.

  • Bhidayasiri R, Truong D. Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management. J Neurol Sci. 273(1-2):156-157, 2008.

  • Bhidayasiri R, Truong DD. Evidence for effectiveness of botulinum toxin for hyperhidrosis. Journal of Neural Transmission 115(4):641-5, 2008.

  • Frei K, Truong D, Wolters E. Case study in Parkinson’s disease. CNS Spectrum 13, 1-8, 2008.

  • Truong D. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's Disease. Clinical Interventions in Aging 4:109–113, 2009.

  • Truong D, Stenner A, Reichel G. Recent development in botulinum toxin therapy. Current Pharmaceutical Design. 15(31): 3671-80, 2009.

  • Truong D, Wolters E. Recognition and Management of Parkinson’s disease during the premotor (prodromal) phase. Expert Review of Neurotherapeutics, 9(6), 847-57, 2009.

  • Frei K, Truong D. Clinical Efficacy and Safety of Botulinum Toxin Type B in Cervical Dystonia. European Neurological Journal. Submitted.

  • Bhidayasiri R., Truong D. Chorea and Related Disorders. Postgraduate Medical Journal 80: 527-534, 2004. 

bottom of page